Study of REGN3500 and Dupilumab in Patients With Asthma

Summary

To assess the effects of REGN3500, dupilumab, and REGN3500 plus dupilumab, compared with placebo, on changes in inflammatory gene expression signatures in sputum induced after a bronchial allergen challenge (BAC) in adults with mild allergic asthma, at week 4 after treatment initiation compared with those at screening.

Timeline

Start

2017-06-15

Primary completion

2019-03-20

Completion

2019-12-09

Drugs

Indications